Product
Middle Dose
1 clinical trial
1 indication
Indication
Myocardial InfarctionClinical trial
Efficacy and Safety of Recombinant Human Thymosin β4(NL005) for Injection in Patients With Acute Myocardial Infarction: a Phase IIb Clinical StudyStatus: Completed, Estimated PCD: 2023-05-26